EXEL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Exelixis Inc (EXEL) does not present a compelling buy opportunity for a beginner, long-term investor at this time. While the company's financial performance is strong, the lack of significant positive catalysts, neutral trading sentiment, and mixed analyst ratings suggest holding off on investment until clearer growth signals emerge.
The technical indicators are moderately positive. The MACD is above 0 and expanding, suggesting bullish momentum. The RSI is neutral at 61.244, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its pivot level of 41.879, with resistance at 42.998 and support at 40.759.
Strong Q4 financial performance with revenue up 5.63% YoY, net income up 74.84% YoY, and EPS up 83.33% YoY. The company has shown consistent growth in profitability metrics.
Analysts have mixed ratings with some downgrades citing competitive pressures, limited high-impact catalysts, and concerns over patent life. Additionally, there is no recent news or significant trading trends among hedge funds or insiders.
In Q4 2025, Exelixis reported revenue growth of 5.63% YoY, net income growth of 74.84% YoY, and EPS growth of 83.33% YoY. However, gross margin slightly declined by 0.93% YoY to 95.58%.
Analyst ratings are mixed. RBC Capital recently lowered its price target to $43, citing competitive pressures. H.C. Wainwright maintains a Buy rating with a target of $54, citing upcoming catalysts. Other firms like Morgan Stanley and BofA have downgraded the stock due to valuation concerns and limited catalysts in 2026.
